Account
Insider Insights
01.02.2022
Increasing prescribing controls on new medicines

According to data from the Ministry of Health 65.1% of medicines admitted to reimbursement in 2021 w...

Read more
Insider Insights
01.02.2022
GPS and specialists prescribe more diabetes

The Italian Medicines Agency has announced that General Practitioners will be able to prescribe mo...

Read more
Insider Insights
01.02.2022
Committee recommends rejecting Rx to non-Rx reques

The committee’s recommendations are forwarded to the Federal Ministry of Health for consideration.

Read more
Insider Insights
01.02.2022
Voluntary payment percentage set at 15

All other aspects of the voluntary scheme remain unchanged.

Read more
Insider Insights
01.02.2022
NICE changes to its methods and processes

The changes cover how topics are chosen, the steps and stages in each evaluation and how evidence is...

Read more
Insider Insights
01.02.2022
Proposals for reforming public and private health

The report looks at four possible scenarios including most notably the creation of a “grande Sécu...

Read more
Insider Insights
01.02.2022
Orphan drugs not included in reference price order

The Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Orphan drugs undergo early benefit assessment

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...

Read more
Insider Insights
01.02.2022
Germany completes early benefit assessments

In addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.